PARGY-LAD

This page has not been fully approved by the PsychonautWiki administrators. It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

PARGY-LAD
Chemical Nomenclature
Common names	PARGY-LAD
Substitutive name	6-propynyl-6-nor-lysergic acid diethylamide, N-Propynyl-nor-LSD, N,N-Diethyl-6-propargyl-6-norlysergamide
Systematic name	(8β)-N,N-Diethyl-6-(prop-2-yn-1-yl)-9,10-didehydroergoline-8-carboxamide
Class Membership
Psychoactive class	Psychedelic
Chemical class	Lysergamide
Routes of Administration
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. ⇣ Oral Dosage Threshold 50 µg Light 125 - 275 µg Common 275 - 500 µg Strong 500 - 700 µg Heavy 700 µg + Duration Total 6 - 8 hours Onset 30 - 45 minutes DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
Interactions

Summary sheet: PARGY-LAD

N-Propynylnorlysergic acid N,N-diethylamide (also known as 6-Propynyl-6-nor- Lysergic acid diethylamide, N-PropynylnorLSD or simply PARGY-LAD) is a novel, obscure synthetic research psychedelic of the lysergamide chemical class that is reported to produce a similar albeit significantly less intense array of LSD-like psychedelic effects when administered. It is a close structural homolog of LSD and its existence was first reported by Alexander Shulgin in his book TiHKAL ("Tryptamines I Have Known and Loved"), although he only briefly mentions it and does not discuss its qualitative features.

PARGY-LAD was first investigated by Andrew J. Hoffman and David E. Nichols in 1984 as part of a series of LSD analogs, which included compounds. AL-LAD and ETH-LAD. . It was later described as an analog of LSD by Alexander Shulgin in the book TiHKAL. It has been reported to be significantly less potent than LSD itself with a light dose reported at 160 micrograms and full activity at 500 micrograms.

Very little data exists about the pharmacological properties, metabolism, and toxicity of PARGY-LAD, and it has little history of human usage. It has recently appeared on the market alongside research chemical psychedelic lysergamides such as AL-LAD, ETH-LAD and PRO-LAD as a legal, grey-market alternative to LSD, and commercially distributed through online research chemical vendors, and is considered to be one of the least popular in the series. It is highly advised to approach this unstudied hallucinogenic substance with the proper amount of precaution and harm reduction practices if one chooses to use it.

Chemistry

Substitutive structure of a lysergamide.

Composition

PARGY-LAD, or 6-propynyl-6-nor-lysergic acid diethylamide, is a synthetic alkaloid of the lysergamide family. PRO-LAD is a structural analog of lysergic acid, with an N,N-diethylamide functional group bound to R_N of the chemical structure. This core polycyclic structure is an ergoline derivative, and has overlapping tryptamine and phenethylamine groups embedded within it (although it is principally classed as a tryptamine).

PARGY-LAD's structure contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (nor-lysergic acid). Unlike LSD, PRO-LAD does not contain a methyl group substituted at R₆ of its nor-lysergic acid skeleton, this is represented by the nor- prefix. Instead, PARGY-LAD is substituted at R₆ with a propynyl group. At carbon 8 of the quinoline a N,N-diethyl carboxamide is bound.

Pharmacology

Further information: Serotonergic psychedelic

PARGY-LAD likely acts as a 5-HT_2A partial agonist. The psychedelic effects are believed to come from PARGY-LAD's efficacy at the 5-HT_2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain an object of scientific elucidation.

This pharmacology section is incomplete. You can help by adding to it.

Subjective effects

This subjective effects section is a stub. As such, it is still in progress and may contain incomplete or wrong information. You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

• Spontaneous tactile sensations - The "body high" of PARGY-LAD can be characterized as prominent in comparison to its accompanying visual and cognitive effects. Like LSD, it can behave as a fast-moving, sharp and location specific or generalized tingling sensation, although this feeling is not necessarily pleasant and often manifests in a neutral way. For some, it is manifested spontaneously at different, unpredictable points throughout the trip, but for most, it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached, which many users have reported as feeling "artificial" or "mechanical."
  • Physical euphoria - This component can occur with the development of spontaneous tactile sensations, but is not as consistent as it is with LSD, and has more of a tendency to produce strongly dysphoric physical sensations.
• Stimulation
• Perception of decreased weight
• Bodily control enhancement
• Stamina enhancement - This component is generally mild in comparison to traditional stimulants.
• Headaches
• Nausea
• Appetite suppression
• Dehydration
• Difficulty urinating or Frequent urination
• Temperature regulation suppression
  • Increased bodily temperature
• Increased blood pressure
• Increased heart rate
• Increased perspiration
• Muscle contractions
• Muscle cramps
• Muscle spasms
• Olfactory hallucinations
• Sublingual numbing
• Excessive yawning
• Watery eyes
• Pupil dilation
• Vasoconstriction
• Wakefulness
• Teeth grinding - This component is considerably less intense when compared with that of substances like MDMA.
• Seizure - This is a very rare effect but can likely happen in those predisposed to them, especially while in physically taxing conditions such as being dehydrated, fatigued or undernourished. However, it should be noted that there are no documented cases of seizures occurring with this compound to date.

Cognitive effects

The cognitive effects of PARGY-LAD can be broken down into several components which progressively intensify proportional to dosage. In comparison to other psychedelics such as psilocybin, AL-LAD and mescaline, ETH-LAD is often described as significantly more stimulating and fast-paced in terms of the specific style of thought stream(s) produced and contains a large number of potential effects, which, it should be noted seems to lead to cognitive and general sensory processing overload at moderate to high doses for reasons that are not currently understood.

The most prominent of these cognitive effects generally include:

• Analysis enhancement
• Anxiety & Paranoia
• Introspection
• Personal bias suppression
• Novelty enhancement
• Conceptual thinking
• Introspection
• Immersion enhancement
• Novelty enhancement
• Increased music appreciation
• Increased sense of humor
  • Laughter fits
• Thought acceleration
• Thought connectivity
• Thought loops
• Language suppression
• Memory suppression
• Confusion
• Déjà vu
• Time distortion - This component has been reported to be particularly pronounced relative to other psychedelics.
• Wakefulness

Visual effects

Enhancements

• Colour enhancement
• Pattern recognition enhancement
• Visual acuity enhancement

Distortions

• Brightness alteration
• Colour shifting
• Depth perception distortions
• Drifting (melting, breathing, morphing and flowing)
• Tracers
• After images
• Diffraction
• Perspective distortions
• Symmetrical texture repetition

Geometry

The visual geometry that is commonly present throughout this trip can be generally described as more similar in appearance to that of MET or 2C-B than psilocin, LSA or DMT. It can be comprehensively described through its variations as primarily intricate in complexity, algorithmic in form, structured in organization, brightly lit, colourful in scheme, synthetic in feel, multicoloured in scheme, flat in shading, sharp in edges, large in size, fast in speed, smooth in motion, angular in its corners, immersive in-depth and consistent in intensity. At higher dosages, it may almost consistently result in states of Level 8A or Level 8B visual geometry.

Hallucinatory states

• Transformations
• Internal hallucinations (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots)

Auditory effects

• Auditory enhancement
• Auditory distortion

Multi-sensory effects

• Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.

Transpersonal effects

It should be noted that these effects are the rarest and least reproducible those that can occur during a psychedelic experience. They are considered unique in that that simply taking more of the substance does not necessarily increase the chance they will occur, and are said to rely more on contextual factors such as the user's set and setting rather than the substance or dose itself. Their fullest manifestations are sometimes called "peak", "transcendent" or "transformative" experiences; however, they can still occur on a conceptual or cognitive level that can leave a lasting positive impact on the user.

• Spirituality enhancement
• Existential self-realization
• Feelings of interdependent opposites
• Feelings of eternalism
  • Feelings of self-design
• Unity and interconnectedness

Combinational effects

• Cannabis - When used in conjunction with cannabis, both the visual and cognitive effects of PARGY-LAD can be intensified and extended with extreme efficiency. This should be used with caution if one is not experienced with psychedelics. Many users sometimes report a dramatically more intense visual trip when combining it with THC concentrates such as hashish as opposed to cannabis flower. However, this can also amplify the anxiety, confusion and psychosis producing aspects of both substances significantly, so extreme caution with this combination is advised.
• Dissociatives - When used in combination with dissociatives, the geometry, euphoria, dissociation and hallucinatory effects are often greatly enhanced. Dissociative-induced holes, spaces, and voids while under the influence of PARGY-LAD have significantly more vivid visuals than dissociatives alone present, and more intense internal hallucinations and confusion.
• MDMA - When used in conjunction with MDMA, the physical and cognitive effects of MDMA are amplified. The visual, physical and cognitive effects of LSD are also intensified with an overwhelming euphoric pleasure manifested through uniquely pleasurable body highs and headspaces, and uniquely colorful and awe-inspiring visuals. It is often recommended to wait at least three to four hours after ingesting LSD to take MDMA so as to avoid coming down from the latter while peaking on the former, but positive experiences have been reported with all possible timings. The synergy between these substances is unpredictable (and likely neurotoxic), and it is best to start with lower dosages than one would take for both substances individually.
• Alcohol - This interaction is not typically recommended due to alcohol’s ability to cause dehydration, depression and thought disorganization which can negatively affect a trip if taken in high dosages. This combination is however reasonably safe in low doses and when used responsibly, this can often take the edge off a trip as well as dull its psychedelic effects in a fashion somewhat similar to benzodiazepines, albeit more stressful on the body.
• Benzodiazepines - When used in combination with benzodiazepines, benzodiazepines can, depending on the dosage, slightly to completely reduce the intensity of the cognitive, physical and visual effects of a PARGY-LAD trip. They are very efficient at stopping bad trips at the cost of amnesia and reduced trip intensity. Caution is advised when acquiring them for this purpose due to the very high addiction potential that benzodiazepines possess.
• Psychedelics - When used in combination with other psychedelics, each drug's physical, cognitive and visual effects intensify and synergize strongly. The synergy between those substances is unpredictable, and for this reason generally not advised. If choosing to combine psychedelics, it is recommended to start with lower dosages than one would take for either substance individually.

Toxicity and harm potential

Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens

The toxicity and long-term health effects of recreational PARGY-LAD do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because PARGY-LAD is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried PARGY-LAD suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

While no formal studies have been conducted, PARGY-LAD is likely not habit-forming and it is reasonable to speculate that the desire to use it can actually decrease with repeated administratino. As with most psychedelics, it likely possesses what is considered an intrinsic, self-regulating aspect to it.

Tolerance to the effects of PARGY-LAD are built almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). PARGY-LAD presents cross-tolerance with [[Cross-tolerance::all psychedelics], meaning that after the consumption of PARGY-LAD all psychedelics will have a reduced effect.

Dangerous interactions

Although many substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be relatively harmless in low doses of each but can still increase the risk of unpredictable injury or death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. Note that the substances listed below refer to LSD specifically; however, there is no reason to believe these negative interactions do not apply equally, if not even more so, to relatively unstudied and structurally similar compounds like PARGY-LAD as well.

• Tramadol - Tramadol lowers seizure threshold and psychedelics may cause occasional seizures.
• Stimulants - Stimulants may provoke anxiety or thought loops.
• Lithium - Individuals who take lithium for bipolar disorder or other psychiatric conditions should not take LSD. There are numerous anecdotal reports of seizures and or unsafe psychosis from this combination.

Legal issues

This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it.

• United Kingdom: As of January 7th, 2015, PARGY-LAD is specifically named in the U.K. Misuse of Drugs Act as a Class A drug.
• Switzerland: On December 1, 2015, Switzerland added PARGY-LAD to the list of controlled substances.
• Latvia - PARGY-LAD is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1th, 2015.

See also

• Responsible use (Hallucinogens)
• Research chemical
• Hallucinogens
• Psychedelic
• Lysergamide
• AL-LAD
• ETH-LAD
• LSD

External links

• PARGY-LAD (Wikipedia)
• Erowid Online Books: "TIHKAL" - #51 PRO-LAD

Literature

• Hoffman, A. J., & Nichols, D. E. (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N (6)-alkyl norlysergic acid N, N-diethylamide derivatives. Journal of Medicinal Chemistry, 28(9), 1252-1255. https://doi.org/10.1021/jm00147a022.
• Watts, V. J., Mailman, R. B., Lawler, C. P., Neve, K. A., & Nichols, D. E. (1995). LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 118(4), 401-409. https://doi.org/10.1007/BF02245940.
• Niwaguchi, T., Nakahara, Y., & Ishii, H. (1976). Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan, 96(5), 673-678. PMID 987200.
• Pfaff, R. C., Huang, X., Marona-Lewicka, D., Oberlender, R., & Nichols, D. E. (1994). Lysergamides Revisited. NIDA Research Monograph, 146, 52-73. PMID: 8742794.